Advertisement

Topics

Arcus Biosciences Announces Pricing of Initial Public Offering

17:53 EDT 14 Mar 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Arcus Biosciences (NYSE: RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced the pricing of its initial public offering of 8,000,000 shares of common stock at ...

Other Sources for this Article

Arcus Biosciences
Jennifer Jarrett, 510-694-6261
jjarrett@arcusbio.com

NEXT ARTICLE

More From BioPortfolio on "Arcus Biosciences Announces Pricing of Initial Public Offering"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...